Core Viewpoint - NovaBridge Biosciences, formerly known as I-Mab, has undergone a corporate name change and will begin trading under the new ticker symbol "NBP" on Nasdaq starting October 30, 2025, as part of its strategic transformation into a global biotechnology platform company focused on innovative medicines [1][2][3] Corporate Transformation - The new corporate brand and website signify a strategic shift towards becoming a global biotechnology platform committed to accelerating access to innovative medicines for patients worldwide [2] - The name change was overwhelmingly approved by shareholders and the Board of Directors during an Extraordinary General Meeting held on October 24, 2025 [1] Business Strategy - The company plans to pursue a dual listing on both Nasdaq and the Hong Kong Stock Exchange (HKEX) to broaden its investor base and enhance trading liquidity [6][7] - NovaBridge has adopted a "hub-and-spoke" business model, creating specialized subsidiary companies to maintain operational focus and agility [9] Pipeline and Product Development - The core asset, givastomig, is a potential best-in-class Claudin 18.2-directed therapy for gastric cancers, currently advancing towards a global randomized Phase 2 study with first patient enrollment expected in Q1 2026 [8][12] - VIS-101, acquired by the newly formed subsidiary Visara, is a bifunctional biologic targeting VEGF-A and ANG2, currently in Phase 2 development and anticipated to be Phase 3-ready in 2026 [11][16] Leadership and Expertise - The company is led by experienced professionals, including Dr. Emmett T. Cunningham, Jr., who has extensive expertise in infectious and inflammatory eye disease [11][12] - NovaBridge aims to leverage deep local insights and global capabilities to develop promising drug candidates across various therapeutic categories [8][13]